By contrast when we administered anti-PD-1 later, at the peak of SPAS-1+ T cell expansion invoked by IRE plus anti-CTLA-4, we observed sustained control of tumor growth, particularly in those mice that did not respond fully to initial dual therapy (Fig. 9). The gene discussed is SPATA19; the disease is neoplasm.